Yardstick Research tear-sheet / pharma & life sciences CRM cohort
Within3
Identity
- Founded: 2007 [VENDOR-CLAIMED - https://within3.com/about-us]
- HQ: Lakewood, Ohio (14701 Detroit Ave, Lakewood, OH 44107) [THIRD-PARTY - https://www.linkedin.com/company/within3]
- Legal entity: Within3 (legal entity name not publicly disclosed)
- Funding: Not publicly disclosed. No venture rounds found on Crunchbase or PitchBook as of research date. [UNKNOWN]
- Headcount: 51-200 (LinkedIn estimate) [THIRD-PARTY - https://www.linkedin.com/company/within3]
- Leadership:
- Lance Hill - Founder & CEO
- Jason Smith - CTO, AI & Analytics
- Kim Cerri - SVP Engineering
- Samantha McAloney - SVP Product Management
- Stephen Mathey - CFO [VENDOR-CLAIMED - https://within3.com/about-us]
- Recent news (last 12 months):
- May 2026 - Within3 exhibited at MAPS EMEA 2026 in Zurich, showcasing the Launch Intelligence platform to medical affairs leaders. [VENDOR-CLAIMED - https://within3.com/blog]
- April 2026 - Attended Fierce Pharma Engage conference; presented on decision velocity challenges in pharmaceutical launch planning. [VENDOR-CLAIMED - https://within3.com/blog]
- April 2026 - Participated in Pharmageddon USA with executive-level thought leadership. [VENDOR-CLAIMED - https://within3.com/blog]
- 2025-2026 - Launched "Dataverse," a data collaboration initiative designed to expand real-world data coverage inside the Launch Intelligence platform. [VENDOR-CLAIMED - https://within3.com/blog]
- 2025-2026 - CTO published positioning document arguing pharma AI benefits from domain-fit models over frontier general-purpose models ("Bigger Is Not Better"). [VENDOR-CLAIMED - https://within3.com/blog]
- Archetype: Life sciences insights management and launch intelligence platform. Within3 aggregates field activity, HCP engagement, social sentiment, claims data, and congress intelligence into a single dashboard used by Medical Affairs, Commercial, and Clinical/R&D teams at pharmaceutical and biotech companies. It positions itself as the category creator of "insights management" for the pharma industry, with a secondary product surface as a virtual advisory board and KOL mapping tool.
Total score: 72.5 / 100
- Stage fit:
- Foundation (<40 readiness): no - Enterprise-sales-only, no self-serve trial, domain-specific implementation. Not a fit for early-stage companies without an established Medical Affairs or Commercial Insights function.
- Pilot (40-59): conditional - The platform can run a scoped pilot around a single brand launch or advisory board program, but the implementation investment and organizational readiness required make it a stretch below mid-market.
- Scale (60-79): yes - This is the primary fit zone. Within3's claim of serving all top 20 global pharma companies and 65% of top 50 global drugs on its platform is the Scale-stage proof point. The platform was designed for mid-to-large pharma commercial and medical affairs teams.
- Optimization (80+): conditional - Suitable for optimization-stage deployments at large pharma with mature cross-functional data integration needs, but the lack of native CRM integrations limits depth at the highest tier.
- One-line verdict: The market-leading insights management and launch intelligence platform for mid-to-large pharma - strongest vertical specialization and named-customer evidence in the cohort, held back by undisclosed compliance certifications and limited workflow integration depth.
Headline numbers
| Metric | Value | Evidence |
|---|---|---|
| Free tier? | No - enterprise sales only | [VENDOR-CLAIMED - https://within3.com/about-us] |
| Pricing | Not publicly disclosed | [UNKNOWN] |
| Customer count | All top 20 global pharma companies; 70,000+ patients and HCPs engaged; 65% of top 50 global drugs discussed on platform | [VENDOR-CLAIMED - https://within3.com/about-us] |
| Platform stat | "7x more feedback, 90% less workload" vs. traditional advisory boards (vendor claim) | [VENDOR-CLAIMED - https://within3.com/about-us] |
Dimension scores
| Dimension | Score | Weight | Weighted | Evidence |
|---|---|---|---|---|
| AI capability depth | 3/4 | 15 | 11.25 | [VENDOR-CLAIMED] Launch Intelligence platform uses domain-fit AI models for social listening, KOL influence mapping, and insight synthesis across structured + unstructured data feeds. CTO has published on intentional choice of domain-fit models over frontier LLMs for pharma. Dataverse real-world data collaboration layer added 2025-2026. Gaps: no published accuracy benchmarks, no named LLM stack, no third-party validation of AI output quality. [VENDOR-CLAIMED - https://within3.com/blog] |
| Workflow integration depth | 2/4 | 20 | 10.0 | [UNKNOWN] No CRM integrations appear in the D1 integrations column for Within3 (integrates_with is empty). The platform describes connectivity to "field activity, HCP engagement, social sentiment, claims data, and congress information" via Dataverse and internal aggregation, but native connectors to Veeva, IQVIA OCE, or Salesforce are not publicly documented. API-based integration is implied but not enumerated. [UNKNOWN - no public integrations page confirmed] |
| Vertical specialization | 4/4 | 20 | 20.0 | [VENDOR-CLAIMED + THIRD-PARTY] Within3 was purpose-built for pharma/life sciences and describes itself as "the world's first insights management platform" for the industry. Customer base covers all top 20 global pharma companies. Summit Series webinars with AstraZeneca, Grifols, and Pfizer executives. Use cases map directly to Medical Affairs, Commercial launch, and KOL engagement workflows. No meaningful horizontal-market positioning. [VENDOR-CLAIMED - https://within3.com/about-us, https://www.linkedin.com/company/within3] |
| Implementation + time-to-value | 3/4 | 5 | 3.75 | [VENDOR-CLAIMED] Vendor claims "reporting time from months to days" and markets rapid insight generation. The platform covers multiple functional personas (Medical Affairs, Commercial, Clinical/R&D), suggesting a scoped single-function deployment is feasible in weeks. No published implementation timeline. [VENDOR-CLAIMED - https://within3.com/about-us] |
| Data + compliance posture (HIPAA/21CFR11) | 3/4 | 20 | 15.0 | [VENDOR-CLAIMED - PARTIAL] SOC 2 (AICPA SOC Compliance Audit) is the only certification explicitly surfaced on vendor-owned pages. HIPAA, 21 CFR Part 11, and ISO 27001 are not confirmed on any public surface as of research date. Privacy policy confirms GDPR compliance and states "reasonable technical, administrative, and physical safeguards." Given the customer base (all top 20 pharma), HIPAA compliance is plausible but [UNKNOWN] without a published trust center or BAA reference. 21 CFR Part 11 support is [UNKNOWN]. [VENDOR-CLAIMED - https://within3.com/privacy-policy; SOC 2 - https://within3.com/about-us] |
| Pricing + scalability | 2/4 | 5 | 2.5 | [UNKNOWN] Pricing is not publicly disclosed on any vendor surface. No tiered plans, no rate card, no published implementation fee schedule. Soft pricing-transparency penalty applied. [UNKNOWN] |
| Vendor strength + named-customer evidence | 4/4 | 15 | 15.0 | [VENDOR-CLAIMED + THIRD-PARTY] Named customers include Pfizer, AstraZeneca, Grifols, Otsuka, Johnson & Johnson, and Abbott (via Summit Series and conference documentation). Claim of serving all top 20 global pharma is a strong cohort differentiator. 70,000+ HCPs and patients on platform. Everest Group and MAPS EMEA conference presence. [VENDOR-CLAIMED - https://within3.com/about-us, https://within3.com/blog] |
| Total | 100 | 77.5 − 5 (soft) = 72.5 |
Pricing detail
Within3 does not publish pricing on any public surface. No tiered plan structure, rate card, or implementation fee schedule was found during research. Pricing is enterprise-negotiated. Buyers should expect:
- Annual subscription model based on brand count, user seats, or functional scope (inferred from enterprise SaaS norms in this segment)
- Implementation and onboarding services likely bundled or priced separately
- Request for quote is the only available path
Soft pricing-transparency penalty applied: no public pricing found. This penalty reduces the headline score by 5 points from the pre-penalty total of 77.5 to 72.5.
Integrations
No CRM or workflow integrations are listed in Within3's D1 record (integrates_with is empty). The platform's Dataverse initiative suggests a data-layer aggregation model rather than point-to-point CRM connectors. No native Veeva Vault CRM, IQVIA OCE, or Salesforce Health Cloud connectors are publicly confirmed. API-based connectivity is implied in vendor positioning but not documented on a public integrations page. Buyers with existing Veeva or Salesforce infrastructure should request a written integration architecture specification before procurement.
Editorial assessment
Within3 sits at a rare intersection in the pharma-CRM cohort: it is not a sales-force automation tool or a next-best-action engine, but rather a layer that turns the noise produced by field activity, HCP advisory programs, social listening, and congress intelligence into a structured insight feed for brand and medical teams. The claim that all top 20 global pharmaceutical companies use the platform is the cohort's strongest named-customer signal, and the Summit Series programming with AstraZeneca, Grifols, and Pfizer executives suggests those relationships are active, not archival.
The platform's commercial and analytical differentiation - consolidating KOL mapping, virtual advisory boards, social sentiment, and launch signals into a single dashboard - maps well to the rubric's vertical specialization dimension, where it earns the cohort's maximum raw score. The CTO's positioning of domain-fit AI models as superior to general-purpose frontier models for pharma tasks reflects genuine product philosophy rather than marketing language, and the Dataverse real-world data expansion is the kind of tractable roadmap move that fits the platform's core thesis.
The gaps are structural rather than feature-level. Within3 does not document HIPAA compliance or 21 CFR Part 11 support on any public surface, which is a notable absence for a platform handling HCP engagement data in FDA-regulated contexts. The SOC 2 reference on the about page is the only public compliance signal. For a vendor serving all top 20 pharma companies, a publicly accessible trust center with audit dates and certification scope would be expected - its absence forces procurement teams to conduct manual diligence that the platform's peers resolve with published documentation. Workflow integration depth is also limited by the absence of native connectors to Veeva, IQVIA OCE, or Salesforce; the platform appears to operate as a destination layer for insights rather than a bidirectional participant in a commercial operations stack.
Pricing opacity compounds these gaps. Enterprise-only negotiation with no public pricing signals means a buyer entering an RFP process has no benchmarking reference. That said, for a buyer that has already reached the scale stage with a large pharma commercial team and an established Medical Affairs function, Within3's market position (all top 20 pharma), platform depth, and launch intelligence specialization represent a strong shortlist candidate.
Best for
- Stage: Scale (60-79). Conditional for Optimization at large pharma with cross-functional integration requirements.
- Company profile: Mid-to-large pharmaceutical or biotech company with an active Medical Affairs team, commercial launch operations, and KOL engagement programs. Buyers with established HCP advisory board programs or congress-level engagement are the primary fit.
- Industry fit: Core pharma commercial and medical affairs. Strong for launch-focused commercial teams, medical science liaison programs, and market access functions at pharmaceutical companies with global brand portfolios.
- Sales motion: Enterprise procurement with dedicated Medical Affairs and commercial technology buyers. Likely multi-stakeholder (Medical Affairs + Commercial Insights + IT). Account-level sales cycle measured in months.
- Annual tooling budget: $100K-$500K+ estimated (based on enterprise SaaS norms for platforms serving all top 20 pharma; no public data).
- Skip if: You need (a) native Veeva Vault CRM or Salesforce Health Cloud bidirectional integration without custom API work, (b) published HIPAA BAA and 21 CFR Part 11 documentation before procurement approval, (c) a self-serve trial or transparent pricing before executive sign-off, (d) next-best-action field force intelligence rather than an insights aggregation and launch analytics layer, or (e) sub-$50K annual tooling budget.
Right-of-reply
Within3 received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Within3 was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Within3 was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.
Right-of-reply gaps
Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:
- HIPAA compliance status. Does Within3 sign a BAA? Is the platform HIPAA-covered-entity or business-associate compliant? Published trust center or compliance page with audit date requested.
- 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 electronic records requirements for FDA submission contexts? What audit trail and e-signature capabilities exist?
- SOC 2 Type II scope and audit date. The AICPA SOC reference on the about page references SOC compliance. Is this SOC 2 Type I or Type II? What is the audit date and scope?
- ISO 27001 status. Held or not held?
- Native CRM integrations. Does Within3 have native Veeva Vault CRM, IQVIA OCE, or Salesforce Health Cloud connectors? What is the integration architecture?
- Funding history. Is the company self-funded, PE-backed, or venture-backed?
- Legal entity name. Is the legal entity "Within3" or a different registered name?
- Headcount. Current employee count for vendor-viability assessment.
Sources
Within3 first-party: - https://within3.com/about-us - https://within3.com/blog - https://within3.com/privacy-policy - https://within3.com/ (homepage)
Third-party: - https://www.linkedin.com/company/within3
Events / conferences referenced: - https://within3.com/blog (MAPS EMEA 2026 recap) - https://within3.com/blog (Fierce Pharma Engage 2026 recap) - https://within3.com/blog (Pharmageddon USA 2026 recap)